pharmaphorum

SEPTEMBER 11, 2022

Analysts at Mizuho have suggested that competition from BMS’ drug could trim Otezla’s 2025 sales from $3 billion to $2 billion, although Amgen is attempting to defend its product by expanded the label of the drug to include mild psoriasis. Otezla was acquired by Amgen for $13.4

FDA 52

FDA Marketing Patients Sales 52

Rep-Lite

JULY 27, 2023

billion by 2025. Moreover, we’ll shed light on the evolution of medical sales techniques and strategies, the impact of technology, and the importance of talent acquisition to thrive in this competitive domain. Attracting and Retaining Top Sales Talent A competitive compensation package is just the beginning.

Sales 52

Sales Medical Medical sales Sales Strategy 52

Medico Reach

AUGUST 30, 2022

By 2025, the campaign hopes to impact the community of three billion people annually. The Anne Arundel’s Medical Center hosted a competition that required participants to submit a selfie with a natural or fake mustache. The competition blended humor with the concerning health issues that men face during their lifetime.

Healthcare 52

Healthcare Healthcare Marketing Medical 52

pharmaphorum

JANUARY 4, 2023

It has been proposed that the amount of these fees charged by the data holder must be transparent, proportionate, and “must not restrict competition” 10. The EC is hoping that, by the end of its current mandate on 31 October 2024, the legislative process will be completed, with the EHDS becoming operational in 2025.

Pharmaceutical 89

Pharmaceutical Electronics Healthcare Healthcare 89

Clarivate

OCTOBER 10, 2022

Fruquintinib will face fierce competition should it be approved in the third- and later-line setting. Fruquintinib was well-tolerated, with a safety profile consistent with that previously reported in other studies. Hutchmed´s fruquintinib is a highly selective and potent oral inhibitor of VEGFR1-3. months; HR: 0.321, P<0.001).

Marketing 52

Marketing Safety Patients Competition 52

European Pharmaceutical Review

FEBRUARY 7, 2023

From 31 January 2025, new and ongoing clinical trials in the EU must be conducted in compliance with the CTR. In addition, the devices must not present an unacceptable risk to patient and user health and safety as established in Articles 94 and 95 of the MDR. Authorisation of the clinical trial, may, however, be obtained later.

Medical 117

Medical Government Marketing Medicine 117

Pharmaceutical Technology

APRIL 20, 2023

Following a tumultuous development cycle, DBV Technologies will now have to conduct an additional safety study of its peanut allergy Viaskin patch in toddlers ages 1–3 years, based on written correspondence from the US Food and Drug Administration (FDA). DBV expects to share topline data from the study in H1 2025.

Food and Drug Administration 52

Food and Drug Administration FDA Safety Prospecting 52

Pharmaceutical Technology

MAY 30, 2023

identifies hidden safety liabilities and efficacy gaps in drug candidates, and DenovAI focuses on the de novo design of antibodies with robust binding capabilities, specifically tailored to desired epitopes. This is the sixth call for applications that AION has launched. and DenovAI were launched last year.

Pharma 84

Pharma Government Prospecting Education 84

Pharmaceutical Technology

APRIL 25, 2023

A few months later, the board of the nonprofit Vaccine Alliance Gavi approved an initial investment of nearly $160 million, to be given between 2022 and 2025, to support the rollout of the malaria vaccine in GAVI-eligible countries. However, making sure the vaccine reaches everyone can be challenging due to the storage requirements.

Food and Drug Administration 69

Food and Drug Administration Government Prospecting Food 69

Pharmaceutical Technology

MAY 30, 2023

identifies hidden safety liabilities and efficacy gaps in drug candidates, and DenovAI focuses on the de novo design of antibodies with robust binding capabilities, specifically tailored to desired epitopes. This is the sixth call for applications that AION has launched. and DenovAI were launched last year.

Pharma 52

Pharma Government Prospecting Education 52